This company listing is no longer active
Resumen de acción H1ZN34
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de Horizon Therapeutics Public Limited Company
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$58.24 |
| 52 Week High | US$61.74 |
| 52 Week Low | US$29.85 |
| Beta | 1.14 |
| 1 Month Change | 1.91% |
| 3 Month Change | -2.53% |
| 1 Year Change | 8.98% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 30.79% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| H1ZN34 | BR Biotechs | Mercado BR | |
|---|---|---|---|
| 7D | 0.9% | 4.2% | 0.9% |
| 1Y | 9.0% | -2.6% | 15.2% |
Rentabilidad vs. Industria: H1ZN34 exceeded the BR Biotechs industry which returned -6.7% over the past year.
Rentabilidad vs. Mercado: H1ZN34 exceeded the BR Market which returned -19.7% over the past year.
Volatilidad de los precios
| H1ZN34 volatility | |
|---|---|
| H1ZN34 Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.9% |
| 10% least volatile stocks in BR Market | 2.2% |
Precio estable de las acciones: H1ZN34 has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: H1ZN34's weekly volatility has decreased from 8% to 3% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2005 | 2,115 | Tim Walbert | www.horizontherapeutics.com |
Resumen de fundamentos de Horizon Therapeutics Public Limited Company
| Estadísticas fundamentales de H1ZN34 | |
|---|---|
| Capitalización bursátil | R$131.44b |
| Beneficios(TTM) | R$2.75b |
| Ingresos (TTM) | R$19.15b |
47.8x
Ratio precio-beneficio (PE)6.9x
Ratio precio-ventas (PS)¿Está H1ZN34 sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de H1ZN34 | |
|---|---|
| Ingresos | US$3.63b |
| Coste de los ingresos | US$828.49m |
| Beneficio bruto | US$2.80b |
| Otros gastos | US$2.28b |
| Beneficios | US$521.48m |
Últimos beneficios comunicados
Dec 31, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 2.28 |
| Margen bruto | 77.17% |
| Margen de beneficio neto | 14.37% |
| Ratio deuda/patrimonio | 50.5% |
¿Cómo se ha desempeñado H1ZN34 a largo plazo?
Ver rendimiento histórico y comparativa